ImQuestSUCCESS
Our Platform for Expedited Drug Discovery and Development

The ImQuestSUCCESS platform is utilized at each and every stage of product development to critically evaluate the potential of a test compound and to assure that **Efficacy**, **Toxicity**, and **Pharmaceutical Properties** of a test compound are evaluated in a comprehensive and interactive way. The platform helps to assure that the best clinical product is chosen for continued investment and development. Successful completion of the platform objectives provides significant confidence in the potential of the test compound to transition to human clinical trials. ImQuestSUCCESS empowers us to work smarter, not harder.

We know time is money. The ImQuestSUCCESS platform enhances the robustness of drug development efforts and reduces the risk of expensive clinical development failures by allowing us to exclude candidates which are likely to fail during advanced preclinical and clinical development at early (and less expensive) time points. The ImQuestSUCCESS platform allows the positive selection of those products with the highest probability of clinical success.

The ImQuestSUCCESS platform consists of interrelated efficacy-defining components for cancer (OncoSENS), infectious disease (MicroSENS, PrevSENS, ViroSENS), and women’s health (FemSENS) with parallel evaluations of *in vitro* and *ex vivo* toxicity (ToxiSENS) and the pharmaceutical properties of clinical candidates (PharmaSENS).

### Pharmaceutics

The pharmaceutics component provides stepwise evaluation of the preformulation and formulation characteristics of a compound to define the best means of delivering a clinical candidate. It also evaluates compound metabolism and physicochemical properties of the drug substance.

**PharmaSENS** - for the evaluation of the pharmaceutical properties of a test compound to determine if the compound is a druggable agent.

### Efficacy

In order to submit an IND, each efficacy-defining program consists of the evaluation of efficacy, range of action, mechanism of action, potential for resistance generation, employment of combination therapy strategies, and animal models of efficacy.

**FemSENS** - for the development of agents pertaining to women’s health, including infectious disease, cancer and inflammatory disease.

**MicroSENS** - for antibiotic discovery and development for hospital and community acquired infections.

**PrevSENS** - for the development of topical microbicides and vaccines to prevent the sexual transmission of viruses, bacteria and fungi.

**ViroSENS** - for the development of infectious disease agents to treat HIV, HCV, HBV, herpesviruses, dengue and other flaviviruses, influenza, respiratory, and enteric viruses.

### Toxicity

The product safety component rapidly evaluates the toxicity of a test compound to a variety of human cells and tissues. Our program also includes *in vitro/ex vivo* drug permeability, metabolism, drug-drug interaction and pharmacokinetic evaluations.

**ToxiSENS** - for the evaluation of the *in vitro*, *ex vivo* and *in vivo* toxicity and safety of test compounds prior to animal safety studies and human clinical trials.